Osteoarthritis (OA) is a major cause of disability worldwide. Over the past years, interest has grown among the scientific community, pharmaceutical companies, and regulatory agencies in the development of drugs that might influence the natural history of structural changes in OA by preventing, retarding, or reversing cartilage breakdown. To be able to assess such drugs, it is essential to identify a valid outcome variable that reflects the natural history of structural changes in OA. Requirement of total joint replacement (TJR) is an interesting outcome, as it is a “hard” endpoint. Limitations exist, however, in the use of this outcome. In this presentation, we will discuss the advantages and limitations of the requirement of TJR as an outcome measure, as well as its alternative: “fulfilling the criteria for TJR”.
Disclosure of Interest None declared